

Wednesday May 18, 2011

(Pre-Conference Day)

7:00am – 7:00pm	REGISTRATION	Willem Burger Hall
8:00am – 5:00pm	GLOBAL REGULATORY PERSPECTIVES WORKSHOP – separate registration fee required	Jurriaanse Zaal
9:00am – 6:15pm	FACT/JACIE CELLULAR THERAPY WORKSHOP – separate registration fee required	Fortis Bank Zaal
	FACT/JACIE CELLULAR THERAPY WORKSHOP BREAKOUT SESSION – separate registration fee required	Plate Zaal/Van der Vorm Zaal
2:30pm – 4:30pm	Corporate Symposium – BD Biosciences (Refer to Corporate Conference Guide for details)	Willem Burger Zaal
5:00pm – 7:00pm	Corporate Symposium – Miltenyi Biotec GmbH (Refer to Corporate Conference Guide for details)	Willem Burger Zaal
7:00pm – 9:30pm	Exhibits Open	Arcadis /Van de Mandele /Jurriaanse Foyer
7:00pm – 7:30pm	Welcome Address	Jurriaanse Zaal
7:30pm – 9:30pm	Welcome Reception in Exhibit Hall	Arcadis /Van de Mandele /Jurriaanse Foyer

Thursday May 19, 2011

7:00am – 4:00pm	REGISTRATION	Willem Burger Hall
7:45am – 8:45am	TECHNICAL SESSION 1 <i>Imaging Cell Therapy</i> Chair: Hervé Petite (France) Speakers: Hervé Petite (France) – Use of bioluminescence imaging for monitoring mesenchymal stem cell survival r Mariann Gyöngyösi (Austria) – Non-invasive tracking of the cardially injected stem cell	Jurriaanse Zaal
	TECHNICAL SESSION 2 <i>Practical Considerations in Cell Selection for Cellular Therapy</i> Chair: Ruud Hulsapas (USA) Speakers: Bruce Levine (USA) – Aspects of magnetic and centrifugal-based cell sorting for clinical trials Ruud Hulsapas (USA) – Practical Considerations in Cell Selection for Cellular Therapy	Plate Zaal/Van der Vorm Zaal
	STRATEGIES FOR COMMERCIALIZATION TRACK 1 <i>Positioning for Phase III Manufacturing</i> Chair: Ian Harris (USA) Speakers: Ian Harris (USA) – What is needed for the manufacture of pivotal batches of cell based products Wouter van't Hoff (USA) – Characterization and potency assay development for MultiStem: An adult bone marrow derived adherent stem cell therapy product	Fortis Bank Zaal
	TECHNICAL APPLICATIONS TRACK 1 <i>Quality and Technical Agreements for Cell Therapy Facilities</i> Chair: Shirley Bartido (USA) Speakers: Shirley Bartido (USA) – Quality and Technical Agreements for Cell Therapy Facilities Andrea Jochheim-Richter (Germany) – Quality and Technical Agreements for Cell Therapy Facilities	Van Rijckevorsel/Ruys Zaal
	PLENARY SESSION 1 – PRESIDENTIAL PLENARY ON MESENCHYMAL STEM CELLS Chair: Ed Horwitz (USA) Speakers: Armand Keating (Canada) – MSCs: Current Clinical Applications and Future Challenges Luc Sensebé (France) – MSC from genetic stability to controls of safety Marc Dalhke (Germany) – MISOT – Mesenchymal Stem Cells in Solid Organ Transplantation	Willem Burger Zaal
9:00am – 10:30am		
10:30am – 11:00am	Coffee Break with Exhibits	

11:00am – 12:15pm

ORAL ABSTRACT PRESENTATIONS 1 – REGENERATIVE MEDICINE AND TISSUE ENGINEERING

Co-Chairs: Ineke Slaper-Cortenbach (*The Netherlands*) and Ivan Martin (*Switzerland*) Willem Burger Zaal

Inositol Hexaphosphate-Loaded Red Blood Cells As Preventive therapy in Sickle Cell Disease (Abstract # 1)

Speaker: Vanessa Bourgeaux (*France*)

24 hr Bone Tissue Formation using Mesenchymal Stem Cells Combined with Effector T Cells and Platelet Enriched Plasma on a Matrix of Hydroxyapatite. Feasibility and Animal Proof of Principles. (Abstract # 2)

Speaker: Gustavo Moviglia (*Argentina*)

Autologous Tenocyte injection (ATI) For the Treatment of Lateral Epicondylitis: Phase I/II Study in Perth (Abstract # 3)

Speaker: Paul Anderson (*USA*)

Intramuscular injection of Mesenchymal Stromal Cells in A Preclinical Model of Lower Esophageal Sphincter injury (Abstract # 4)

Speaker: Benedetta Mazzanti (*Italy*)

Development of Pharmacologically Active Microcarriers Transporting Stem Cells and Releasing Growth Factors For Cardiac Stem Cell Regeneration (Abstract # 5)

Speaker: Jean-Pierre Karam (*France*)

ORAL ABSTRACT PRESENTATIONS 2 – HEMATOPOIETIC STEM CELLS

Co-Chairs: Fred Falkenburg (*The Netherlands*) and Christian Chabannon (*France*) Jurriaanse Zaal

19F MRI Cellular Tracer Preserves the Differentiation Potential of Hematopoietic Stem Cells (Abstract # 6)

Speaker: Brooke Helfer (*USA*)

Automation of the Colony-Forming Cell Assay For Measuring Hematopoietic Progenitors in Cord Blood (Abstract # 7)

Speaker: Bert Wognum (*Canada*)

MT1-MMP Is involved in the Mobilization and Homing of Hematopoietic Stem/Progenitor Cells (Abstract # 8)

Speaker: Anna Janowska-Wieczorek (*Canada*)

High Definition Flow Cytometry Markers Provide Clear Resolution of Different HSC and MK-P Populations and their Subsets in Normal and Disease States (Abstract # 9)

Speaker: Varda Deutsch (*Israel*)

ORAL ABSTRACT PRESENTATIONS 3 – LABORATORY PRACTICES/LEGAL & REGULATORY AFFAIRS

Co-Chair: Martino Introna (*Italy*) and Martin Hildebrandt (*Germany*) Van Rijkvorseel/Ruys Zaal

Implementing ISBT 128 Standards as a Traceability Tool in a Cellular Therapy Facility: the Experience of the Ulice Program (2006-2010) (Abstract # 11)

Speaker: Olivier Giet (*Belgium*)

Comparison and Validation of Chimerism in Pediatrics Recipients of Hematopoietic Stem Cell Transplantation (HSCT) A Comparison Between Two Methods: Real-Time Pcr (QRT-PCR) Vs. Variable Number Tandem Repeats (VNTR) (Abstract # 12)

Speaker: Morris Kletzel (*USA*)

Post Thaw CD34 Recovery and Viability of Hematopoietic Progenitor Cells Using A Simplified Dilution Method and a Modified Gating and Analysis Strategy (Abstract # 13)

Speaker: Nicole Prokopishyn (*Canada*)

Development of A Process to Determine the Effect of DMSO On Microbiology Culture Samples (Abstract # 14)

Speaker: Lizette Caballero (*USA*)

Conducting Affordable Cell Therapy Clinical Trials in India - Competency of the CRO to meet Regulatory Guidelines (Abstract # 15)

Speaker: Kenneth Harris (*USA*)

STRATEGIES FOR COMMERCIALIZATION TRACK 2

Cell Characterization, Potency, and Comparability Studies

Fortis Bank Zaal

Chair: Scott Burger (*USA*)

Speakers:

Scott Burger (*USA*) – US FDA Expectations for Cell Therapy Potency Testing

Janet Glassford (*UK*) – Potency Assays for Cell Therapies: A European Regulator's Perspective

Anne Plant (*USA*) – Assurance in Cell Measurements

12:15pm – 1:45pm

Lunch with Exhibits

Fortis Bank Zaal

12:30pm – 1:30pm

Corporate Tutorial – BioLife Solutions Inc. (*Refer to Corporate Conference Guide for details*)

Fortis Bank Zaal

Corporate Tutorial - Thermo Scientific (*Refer to Corporate Conference Guide for details*)

Jurriaanse Zaal

1:45pm – 3:15pm

PLENARY SESSION 2 – REGENERATIVE MEDICINE AND TISSUE ENGINEERING

Willem Burger Zaal

Chair: Ivan Martin (*Switzerland*)

Speakers:

Anthony Hollander (*UK*) – Cartilage tissue engineering: are we ready to translate into the clinic?

Ivan Martin (*Switzerland*) – Challenges in 3D tissue graft manufacturing

Matthias Lutolf (*Switzerland*) – Smart materials for programming stem cell fate in situ

3:15pm – 3:30pm	Coffee Break with Exhibits	
3:30pm – 5:00pm	WORKSHOP 1 <i>Ex-Vivo Expansion (Joint Session with EBMT)</i> Co-Chairs: Christian Chabannon (France), Alejandro Madrigal (UK) Speakers: Luc Douay (France) – From Stem Cells to Red Blood Cells in vitro: Perspectives for Transfusion Medicine Anthony Boitano (USA) – Aryl hydrocarbon receptor antagonists promote expansion of human hematopoietic stem cells Arnon Nagler (Israel) – Novel strategies for ex vivo expansion of human umbilical cord blood for clinical transplantation	Willem Burger Zaal
	WORKSHOP 2 <i>Mesenchymal Stem/Stromal Cells and Tumors</i> Chair: Massimo Dominici (Italy) Speakers: Jacques Galipeau (USA) – MSCs Bite Back – MSCs as antigen presenting cells for cancer immunotherapy Frank Marini (USA) – Mesenchymal stem/stromal cells: their role in tumor stroma development and as potent anti-cancer cellular vehicles Massimo Dominici (Italy) – Transforming MSC from regenerative tools in killer cells for cancer: the Mesenkillers	Jurriaanse Zaal
	WORKSHOP 3 <i>Antigen Specific T Cells</i> Chair: Catherine Bollard (USA) Speakers: Catherine Bollard (USA) – Priming and Expanding Virus-Specific T Cells from Naïve Cord Blood John Barrett (USA) – Approaches to Generating Leukemia Antigen Specific T Cells Inge Jedema (The Netherlands) – Priming and Isolation of Virus and mHag-specific T Cells from Adult Naïve T Cell Compartments	Plate Zaal/Van der Vorm Zaal
	STRATEGIES FOR COMMERCIALIZATION TRACK 3 <i>Advanced Automation for Autologous Processing</i> Chair: Jon Rowley (USA) Speakers: Rosemary Drake (UK) – Challenges in ex-vivo expansion of cell therapy products and automated manufacturing Simon Mauch (Germany) – Integrated automation for the development and manufacturing of cellular therapies David James (Australia) – Automation is critical but only part of the solution	Fortis Bank Zaal
	TECHNICAL APPLICATIONS TRACK 2 <i>Safety Testing for Cell Therapy Products: Requirements, Relevance, and New Technologies</i> Chair: Mark Bonyhadi (USA) Speakers: Scott Burger (USA) – Regulatory Requirements for Safety Testing Marianna Sabatino (USA) – Determining if Mesenchymal Stromal Cells Have Passed (Passaged) Their Prime Mark Bonyhadi (USA) – Technologies for Rapid Testing	Van Rijkceversel/Ruys Zaal
5:00pm – 6:00pm	POSTER SESSION 1	Willem Burger Hall
5:00pm – 7:30pm	INDUSTRY COMMUNITY NETWORKING RECEPTION <i>Invitation Only</i>	Van der Vorm/Plate Zaal
6:00pm – 7:00pm	LAB PRACTICES COMMITTEE MEETING	Fortis Bank Zaal

Friday May 20, 2011

7:00am – 4:00pm	Registration	Willem Burger Hall
7:30am – 8:30am	TECHNICAL SESSION 3 <i>Potency Assays in Stem Cell Based Therapeutics</i> Chair: Rosaria Giordano (Italy) Speakers: Jan de Boer (The Netherlands) – An in vitro diagnostic marker for the efficacy of human MSC-based bone tissue engineering Monica Moro (Italy) – How we can see them	Jurriaanse Zaal
	TECHNICAL SESSION 4 <i>ES/iPS Cells</i> Chair: Harald Mikkers (The Netherlands) Speakers: Harald Mikkers (The Netherlands) – iPS cells for treating blood disorders Lyn Healy (UK) – Banking of hESC and iPS cell lines for research and clinical use	Plate Zaal/Van der Vorm Zaal

7:30am – 8:30am

STRATEGIES FOR COMMERCIALIZATION TRACK 4

Risk Assessments

Fortis Bank Zaal

Chair: Christopher Bravery (UK)

Speakers:

Christopher Bravery (UK) – *The EU risk-based approach: what does it mean?*

Jean Stanton (USA) – *Application of Quality Risk Management Tools for Cell Therapy Manufacturing*

TECHNICAL APPLICATIONS TRACK 3

Environmental Monitoring: How much is enough

Van Rijkvorschel/Ruys Zaal

Chair: Kasper Westinga (The Netherlands)

Speaker:

Philip de Vries (The Netherlands) – *Environmental Monitoring in a Dutch University Hospital GMP Production Facility*

Lynn O'Donnell (USA) – *Environmental Monitoring: How much is enough? A U.S. Perspective*

8:45am – 10:15am

PLENARY SESSION 3 – CARDIOVASCULAR CELL THERAPY

Willem Burger Zaal

Chair: Stefanie Dimmeler (Germany)

Speakers:

Douglas Losordo (USA) – *Repair by bone marrow-derived cells: experimental and clinical insights*

Karl-Ludwig Laugwitz (Germany) – *Human iPSC models of cardiac disease*

Stefanie Dimmeler (Germany) – *microRNAs in cardiovascular repair*

10:15am – 10:45am

Coffee Break with Exhibits

10:45am – 12:15pm

ORAL ABSTRACT PRESENTATIONS 4 – BASIC BIOLOGY OF NON-HEMATOPOIETIC STEM CELLS/NON-HEMATOPOIETIC STEM CELLS TOWARDS THE CLINIC

Willem Burger Zaal

Co-Chairs: Massimo Dominici (Italy) and Luc Sensebé (France)

A Novel Strategy to Enhance Mesenchymal Stem Cell Migration and Therapeutic Efficacy (Abstract # 16)

Speaker: Christodoulos Xinaris (Italy)

The Role of CD44 in the Participation of Mesenchymal Stem/Stromal Cell (MSC) to the Tumor Microenvironment (Abstract # 17)

Speaker: Frank Marini (USA)

Tumour-Derived Stromal Cells Share Immunomodulatory Properties with Multipotent Mesenchymal Stromal Cells (Abstract #18)

Speaker: Friederike Gieseke (Germany)

Treatment of Steroid Resistant Grade II to IV Acute GVHD By infusion of Mesenchymal Stromal Cells Expanded with Platelet Lysate – A Phase I/II Study (Abstract # 19)

Speaker: Ineke Slaper-Cortenbach (The Netherlands)

Repeated infusions of Allogeneic MSC's Maintain Accelerated Growth in Children with Severe Osteogenesis Imperfecta (Abstract # 20)

Speaker: Ed Horwitz (USA)

A Short Pretreatment with Bortezomib Circumvents the Limitations of Mesenchymal Stem Cells' in Vivo Performance, Providing Significant Clinical Benefit in Experimental Arthritis (Abstract # 21)

Speaker: Anastasia Papadopoulou (Greece)

ORAL ABSTRACT PRESENTATIONS 5 – IMMUNOTHERAPY & DENDRITIC CELLS

Jurriaanse Zaal

Co-Chairs: John Barrett (USA) and Derek Hart (Australia)

Multi-Center Clinical Trial of Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia (Abstract # 22)

Speaker: Zhaohui Zheng (USA)

Dendritic Cell Vaccination in Leukemia and Aids: An Update (Abstract # 23)

Speaker: Zwi Berneman (Belgium)

Autologous Cellular therapy Open Label Phase I Study in Chronic Active Crohn's Disease (CACD) with Type 1 Regulatory (TR1) Lymphocytes (CATS1) (Abstract #24)

Speaker: Nathalie Chossat-Clerget (France)

Selective Graft Versus Leukemia Reactions After Donor Lymphocyte infusion Coincide with Minor Histocompatibility Antigen Responses in Graft Versus Host Disease Free Patients (Abstract # 25)

Speaker: Cornelis A.M. van Bergen (The Netherlands)

Allogeneic Cytokine-induced Killer Cells Demonstrate Anti-Tumour Activity in Patients Who Relapse After Allogeneic Haemopoietic Stem Cell Transplant For Haematological Malignancies (Abstract # 26)

Speaker: Yeh-ching Linn (Singapore)

Tolerogenic Dendritic Cells For Type 1 Diabetes Immunotherapy (Abstract # 27)

Speaker: Jaroslav Michalek (Czech Republic)

10:45am – 12:15pm	<p>STRATEGIES FOR COMMERCIALIZATION TRACK 5 <i>Decreasing Corporate Risk for Cell Therapy Programs</i> Fortis Bank Zaal Chair: Dawn Driscoll (Australia) Speakers: Natalie Mount (UK) -Using excellence in clinical program design to mitigate corporate risk for cell therapy products David James (Australia) – The manufacturing investment dilemma Paul Anderson (Australia) – Portfolio Diversification in Regenerative Medicine – Strategies for Decreasing Risk</p>
	<p>TECHNICAL APPLICATIONS TRACK 4 <i>CD34 enumeration, how and when 2011</i> Van Rijckevorsel/Ruys Zaal Chair: Varda Deutsch (Israel) Speakers: Frank Preijers (The Netherlands) – Prerequisites for a reliable CD34 determination Joanne Kurtzberg (USA) – Enumeration of CD34 from fresh and cryopreserved human cord blood Lubomir Arseniev (Germany) – Cellular quality control of haematopoietic grafts: regulatory environment, validation and justification of chosen methods</p>
12:15pm – 1:45pm	<p>Lunch with Exhibits</p>
12:30pm – 1:30pm	<p>ANNUAL GENERAL MEETING Van der Vorm/Plate Zaal</p> <p>Corporate Tutorial – Biosafe SA (Refer to Corporate Conference Guide for details) Willem Burger Zaal</p> <p>Corporate Tutorial – CellGenix GmbH & Afc (Refer to Corporate Conference Guide for details) Jurriaanse Zaal</p>
1:45pm – 3:15pm	<p>PLENARY SESSION 4 – T CELL IMMUNOTHERAPY Willem Burger Zaal Chair: Fred Falkenburg (The Netherlands) Speakers: Fred Falkenburg (The Netherlands) – Alloreactive T cells for the treatment of leukemia Ton Schumacher (The Netherlands) – Dissection of cell therapy-induced cytotoxic T cell responses in melanoma Emma Morris (UK) – Translation of immunotherapy using WT-1 and CMV specific TCR gene transfer into the clinic</p>
3:15pm – 3:30pm	<p>Coffee Break with Exhibits</p>
3:30pm – 5:00pm	<p>WORKSHOP 4 <i>How to improve in vivo vascularisation (Joint Session with TERMIS-EU)</i> Willem Burger Zaal Co-Chairs: Ineke Slaper-Cortenbach (The Netherlands), Gerjo van Osch (The Netherlands) Speakers: Gerjo van Osch (The Netherlands) – The importance of vascularisation and different ways to obtain vascularisation Sabine Fuchs (Germany) – Neovascularization strategies in tissue engineering based on natural cell to cell interactions Heike Walles (Germany) – The use of decellularized tissues to provide a scaffold for rapid vascularisation</p> <p>WORKSHOP 5 <i>Dendritic Cells</i> Jurriaanse Zaal Chair: Gunner Kvalheim (Norway) Speakers: Gunner Kvalheim (Norway) – DC vaccines targeting the tumors stem cells Delores Schendel (Germany) – Young, TLR-activated DCs display optimal characteristics for vaccine use Derek Hart (Australia) – Dendritic cell subsets and cross-presentation: the potential benefits of receptor targeted antigen loading</p> <p>STRATEGIES FOR COMMERCIALIZATION TRACK 6 Fortis Bank Zaal <i>Challenges of Commercial Development of Pluripotent hES</i> Chair: Anthony Davies (USA) Speakers: Anthony Davies (USA) – Development of Human Embryonic Stem Cell-Derived Therapeutics Manufacturing to Support Future Commercialization James Lawford Davies (UK) and Alexander Denoon (UK) – Negotiating the Regulatory and IP Hurdles Howard Levine (USA) – Challenges in the GMP manufacturing of pluripotent hES: Lessons learned from monoclonal antibodies</p> <p>TECHNICAL APPLICATIONS TRACK 5 <i>Establishing GMP Facilities with QA Oversight in Academic Centers for Phase I/II Clinical Trials</i> Van Rijckevorsel/Ruys Zaal Co-Chairs: Shirley Bartido (USA), Martin Hildebrandt (Germany) Speakers: Shirley Bartido (USA) – GMP Facilities in US Academic Centers: their Trials and Tribulations Martin Hildebrandt (Germany) – Academic GMP – Industry standards in a non-industry environment Martino Introna (Italy) – Feasibility of a GMP Facility inside a Public Hospital in Italy Sven Becker (Germany) – A surprisingly big step: from an academic scientist to a pharmaceutical entrepreneur</p>

17th ISCT ANNUAL MEETING

5:00pm – 6:00pm

POSTER SESSION 2

Willem Burger Hall

6:00pm – 11:00pm

GALA EVENT *separate registration fee required*

6:00pm – 7:30pm

Reception at Rotterdam City Hall

7:30pm – 11:00pm

Dinner, SS Rotterdam

Saturday May 21, 2011

7:00am – 3:00pm

Registration

Willem Burger Hall

7:30am – 8:30am

TECHNICAL SESSION 5

Adipose Mesenchymal Progenitors

Jurriaanse Zaal

Chair: Louis Casteilla (France)

Speakers:

Louis Casteilla (France) – *Isolation and Biology of Adipose derived stromal cells: comparison with bone marrow mesenchymal stem cells*

Jeffrey Gimble (USA) – *Adipose-derived cells: How does that translate?*

Christian Dani (France) – *Human adipocyte progenitors: Maintenance ex vivo and regulation of their self-renewal and differentiation*

TECHNICAL SESSION 6

Ancillary Materials

Plate Zaal/Van der Vorm Zaal

Chair: Fouad Atouf (USA)

Speakers:

Fouad Atouf (USA) – *Ancillary Materials Used in Cell Manufacturing: Qualification Programs and Quality Attributes*

Ralf Sanzenbacher (Germany) – *Manufacture of Somatic Cell Therapy and Tissue-engineered Products: Considerations on Quality Aspects*

STRATEGIES FOR COMMERCIALIZATION TRACK 7

Personalized Approach to Cell and Gene Therapy

Fortis Bank Zaal

Chair: Philippe Leboulch (France)

Speakers:

Philippe Leboulch (France) – *Lentiviral therapies for genetic disorders: illustration with adrenoleukodystrophy and the beta-hemoglobinopathies*

Ronnda L. Bartel (USA) – *Ixmyelocel-T - A New Therapy for Severe Chronic Cardiovascular Disease*

TECHNICAL APPLICATIONS TRACK 6

The Essentials of Validation, Qualification and Verification

Van Rijckevorsel/Ruys Zaal

Chair: Lizette Caballero (USA)

Speakers:

Lizette Caballero (USA) – *Qualification and Validation of new freezing containers: our experience*

Ulrike Koehl (Germany) – *Validation and flow cytometric quality control for CD3/CD19 depleted grafts*

8:45am – 10:15am

PLENARY SESSION 5 – CANCER STEM CELLS

Willem Burger Zaal

Chair: Sir Walter Bodmer (UK)

Speakers:

Sir Walter Bodmer (UK) – *Cancer stem cells from colorectal cancer cell lines*

Marc van de Wetering (The Netherlands) – *Lgr5 Intestinal Stem Cells in self-renewal and cancer*

Calvin Kuo (USA) – *Modeling Colon Stem Cells and Neoplasia Using Primary Explant Cultures Containing an Endogenous Wnt-dependent Niche*

10:15am – 10:45am

Coffee Break with Exhibits

10:45am – 11:45pm

ORAL ABSTRACT PRESENTATIONS 6 – CELL AND GENE THERAPY/CELLULAR GENE TRANSFER

Willem Burger Zaal

Chair: Paolo Madeddu (UK) and Philippe Leboulch (France)

CCR5 Disrupted CD4+ T Cells Can Be Consistently Manufactured At Clinical Scale From HIV+ Patients with Suboptimal CD4+ Counts (250-500 Cells/mm³) (Abstract # 28)

Speaker: Martin Giedlin (USA)

Immune Responses to Transgene and Retroviral Vector in Patients Treated with Ex Vivo Engineered T-Cells (Abstract # 29)

Speaker: Cor Lamers (The Netherlands)

Clinical Scale Electroporation of T Cells with RNA Encoding a Chimeric Antigen Receptor (CAR) Mediates Regression of Human Metastatic Mesothelioma at a Fraction of the Cost and Regulatory Burden of Viral Vectors (Abstract # 30)

Speaker: Andrea Brennan (USA)

Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRzeta and 4-1BB Signaling Domains: in Vivo Expansion, Persistence and Anti-Tumor Activity in Patients with Chemotherapy Resistant or Refractory CLL (Abstract # 31)

Speaker: Bruce Levine (USA)

10:45am – 11:45pm	<p>ORAL ABSTRACT PRESENTATIONS 7 – TRANSLATIONAL PROCESS DEVELOPMENT/ CARDIOVASCULAR REGENERATION Chair: Tracey Lodie (USA) and Francesco Lanza (Italy) <i>Jurriaanse Zaal</i> <i>From Concept to Patient Treatment: A Clinical Trial of Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (Abstract # 32)</i> Speaker: Allan Dietz (USA) <i>Cell Characterization: Developing Assays to Address the Biological Parameters of Identity and Potency (Abstract # 33)</i> Speaker: Jessica Carmen (USA) <i>Combined Transcriptomic and Proteomic Approach Identifies Several Putative Paracrine Factors of Fetal Mesenchymal Stem Cells (Abstract # 35)</i> Speaker: Patrizia Danieli (Italy)</p> <p>TECHNICAL APPLICATIONS TRACK 7 <i>Van Rijkceversel/Ruys Zaal</i> <i>ISBT 128 Labeling: We've implemented, and so can you!</i> Chair: Ineke Slaper-Cortenbach (The Netherlands) Speakers: Boris Calmels (France) – Implementation of ISBT 128 through the development of an ISBT 128-compliant software for labeling CT products Giovanna Cameron (Canada) – Implementing ISBT 128 for a Multisite BMT Program</p>
11:45pm – 1:15pm	Lunch with Exhibits
11:45am – 1:15pm	<p>NETWORKING SESSION FOR OPERATIONS SPECIALISTS <i>Fortis Bank Zaal</i> <i>(See page 2 for more details)</i></p>
1:15pm – 2:45pm	<p>WORKSHOP 6 <i>Willem Burger Zaal</i> <i>New Gene Transfer Technologies (Joint Session with ESGCT)</i> Co-Chairs: Cor Lamers (The Netherlands), Paolo Madeddu (UK) Speakers: Zsuzsanna Izsóvá (Germany) – Translating transposons into cellular therapies: victories and challenges Shamim Rahman (Germany) – Cut & Paste – Designer Nucleases for Targeted Genome Editing Axel Rethwilm (Germany) – New developments in viral gene transfer</p> <p>WORKSHOP 7 <i>Jurriaanse Zaal</i> <i>Lung Regeneration</i> Chair: Dan Weiss (USA) Speakers: Dan Weiss (USA) – Cell Therapy and Bioengineering Approaches for Lung Repair and Regeneration Sam Janes (UK) – Cell Therapy for Lung Cancer and the Roadmap Ahead</p> <p>STRATEGIES FOR COMMERCIALIZATION TRACK 8 <i>Fortis Bank Zaal</i> <i>Strategies for Allogeneic Cell Therapy Commercialization</i> Chair: Stewart Abbot (USA) Speakers: Kilian Kelly (Australia) – Commercialization of Allogeneic Mesenchymal Precursor Cells Frida Grynspan (Israel) – Commercialization strategies for the development of PLX-PAD; placental expanded adherent stromal cells, an "off the shelf" product</p> <p>TECHNICAL APPLICATIONS TRACK 8 <i>Van Rijkceversel/Ruys Zaal</i> <i>Process Development: Optimization and qualification of processes for maintaining quality parameters of therapeutic cells</i> Chair: Jon Rowley (USA) Speakers: Miguel Carrion (USA) – Developing and transferring cell culture processes into manufacturing Ryan Guest (UK) – Post-culture processing of a personalised cellular therapeutic product Erik Woods (USA) – Packaging Considerations and Cryopreservation of Cell Therapy Products</p>
2:45pm – 2:55pm	Break
2:55pm – 4:25pm	<p>PLENARY SESSION 6 – EMBRYONIC TO ADULT STEM CELLS <i>Willem Burger Zaal</i> Chair: Elaine Dzierzak (The Netherlands) Speakers: Takumi Era (Japan) – Origin of mesenchymal stem cell Elaine Dzierzak (The Netherlands) – the development of hematopoietic stem cells: Endothelial to hematopoietic transition Catherine Verfaillie (Belgium)</p>